Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants
Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Summary
A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants
Official title: A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-04-28
Completion Date
2027-11-05
Last Updated
2026-04-14
Healthy Volunteers
Yes
Conditions
Interventions
BW-20805
Cohort 1 will receive SC administrations of BW-20805 on Day1.
BW-20805
Group 2 will receive SC administrations of BW-20805 on Day1
BW-20805-2
Group 3 will receive SC administrations of BW-20805-2 on Day1.
Locations (1)
Nucleus Network Pty Ltd.
Melbourne, Victoria, Australia